STAAR Surgical’s (STAA) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of STAAR Surgical (NASDAQ:STAA) in a research note released on Tuesday,Benzinga reports.

Other research analysts have also recently issued research reports about the company. Stephens upgraded STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. Canaccord Genuity Group decreased their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $42.83.

STAAR Surgical Trading Down 3.2 %

Shares of STAA stock opened at $23.12 on Tuesday. The company has a market cap of $1.14 billion, a PE ratio of 52.55 and a beta of 0.63. The company’s fifty day simple moving average is $26.31 and its 200-day simple moving average is $32.87. STAAR Surgical has a 52 week low of $22.40 and a 52 week high of $52.68.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. bought 53,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were acquired at an average price of $24.24 per share, for a total transaction of $1,296,840.00. Following the purchase, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. This trade represents a 0.50 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.00% of the stock is currently owned by corporate insiders.

Institutional Trading of STAAR Surgical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in shares of STAAR Surgical by 0.7% in the 2nd quarter. Rhumbline Advisers now owns 146,775 shares of the medical instruments supplier’s stock valued at $6,988,000 after acquiring an additional 1,039 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in STAAR Surgical by 0.7% in the second quarter. Victory Capital Management Inc. now owns 162,338 shares of the medical instruments supplier’s stock worth $7,729,000 after purchasing an additional 1,153 shares during the period. Los Angeles Capital Management LLC bought a new stake in STAAR Surgical during the second quarter valued at $440,000. ClariVest Asset Management LLC acquired a new stake in shares of STAAR Surgical during the second quarter worth $1,223,000. Finally, Jupiter Asset Management Ltd. bought a new position in shares of STAAR Surgical in the 2nd quarter worth about $1,983,000. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.